International Journal of Clinical Research

Objective To investigate the impact of anticoagulant therapy on coagulation function changes and clinical outcomes in patients with early-onset severe preeclampsia. Methods A total of 80 patients with early-onset severe preeclampsia from 2023 to 2025 were randomly assigned to either standard treatment or anticoagulant therapy, receiving either conventional treatment or combined conventional-anticoagulant therapy respectively. Results After treatment, the anticoagulant therapy group showed significantly better improvements in prothrombin time, activated partial thromboplastin time, fibrinogen, and D-dimer levels compared to the conventional treatment group (P <0.05). Additionally, the anticoagulant therapy group had a higher rate of vaginal delivery (P <0.05). The outcomes for preterm birth, fetal growth restriction, and neonatal asphyxia were also superior in the anticoagulant therapy group (P <0.05). Conclusion Anticoagulant therapy can effectively improve coagulation function and maternal-fetal outcomes in patients with early-onset severe preeclampsia, making it a clinically valuable treatment option worthy of promotion.

Early-onset severe preeclampsia; Coagulation function; Anticoagulation therapy; Low molecular weight heparin calcium; Maternal and infant outcomes